In vitro plasma stability, permeability and solubility of mercaptoacetamide histone deacetylase inhibitors

International Journal of Pharmaceutics

Volumn 361, Issue 1-2, 2008, Pages 19-25

  Konsoula, Roula ^a   Jung, Mira ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

Histone deacetylase inhibitors (HDACIs); Lipophilicity; Mercaptoacetamides; Permeability; Plasma stability; Solubility

Indexed keywords

6 [(2 MERCAPTOACETYL)AMINO N 8 QUINOLINYLHEXAMIDE]; HISTONE DEACETYLASE INHIBITOR; HYDROCHLORIC ACID; MERCAPTOACETAMIDE DERIVATIVE; N [5 [(4 DIMETHYLAMINOBENZOYL)AMINO]PENTYL] 2 MERCAPTOACETAMIDE; S2; VORINOSTAT; W2;

APICAL MEMBRANE; ARTICLE; BASOLATERAL MEMBRANE; CELL STRAIN CACO 2; DRUG HALF LIFE; DRUG PENETRATION; DRUG POTENCY; DRUG SCREENING; DRUG SOLUBILITY; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTESTINE MUCOSA; LIPOPHILICITY; MONOLAYER CULTURE; MOUSE; NONHUMAN; PERMEABILITY; PH; PRIORITY JOURNAL; RAT; SWINE;

ACETAMIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CACO-2 CELLS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROGEN-ION CONCENTRATION; HYDROPHOBICITY; HYDROXAMIC ACIDS; INTESTINAL MUCOSA; MICE; NEOPLASMS; PERMEABILITY; RATS; SOLUBILITY; SWINE;

EID: 47949092210     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2008.05.001     Document Type: Article

References (38)

1. Amidon G.L., Lennermas H., Shah V.P., and Crison J.R. A theoretical basis for a biopharmaceutical drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12 (1995) 413-420
2. Anandan S.K., Ward J.S., Brokx R.D., Bray M.R., Patel D.V., and Xiao X.X. Mercaptoamide-based non-hydroxamic acid type histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 1969-1972
3. Artursson P., and Karlson J. Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial (Caco-2) cells. Biochem. Biophys. Res. Commun. 175 (1991) 880-885
4. Artursson P., Palm K., and Luthman K. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv. Drug Deliv. Rev. 46 (2001) 27-43
5. Avdeef A., and Twsta B. Physicochemical profiling in drug research: a brief survey of the state of the art of experimental techniques. Cell Mol. Life Sci. 59 (2002) 1681-1689
6. Camenisch G., Alsenz J., Van De Waterbeemd H., and Folkers G. Estimation of permeability by passive diffusion through Caco-2 cell monolayers using the drugs' lipophilicity and molecular weight. Eur. J. Pharm. Sci. 6 (1998) 321-329
7. Chen B., Petukhov P.A., Jung M., Velena A., Eliseeva E., Dritschilo A., and Kozikowski A.P. Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 15 (2005) 1389-1392
8. Delie F., and Rubas W. A human colonic cell line sharing similarities with enterocytes as a model to examine oral absorption: advantages and disadvantages of the Caco-2 model. Crit. Rev. Ther. Drug Carrier Syst. 14 (1997) 221-286
9. Di L., Kerns E.H., Hong Y., and Chen H. Development and application of high throughput plasma stability assay for drug discovery. Int. J. Pharm. 297 (2005) 110-119
10. Furumai R., Matsuyama A., Kobashi N., Lee K.H., Nishiyama M., Nakajima H., Tanaka A., Komatsu Y., Nishino N., Yoshida M., and Horinouchi S. FK228 (depsipeptide) as a neutral prodrug that inhibits class I histone deacetylases. Cancer Res. 62 (2002) 4916-4921
11. Hunter J., Jepson M.A., Tsuruo T., Simmons N.L., and Hirst B.H. Functional expression of P-glycoprotein in apical membranes of human intestinal Caco-2 cells. Kinetics of vinblastine secretion and interaction with modulators. J. Biol. Chem. 268 (1993) 14991-14997
12. Johnstone R.W. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1 (2002) 287-299
13. Jung M., Brosch G., Kölle D., Scherf H., Gerhäuser C., and Loidl P. Amide analogues of Trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation. J. Med. Chem. 42 (1999) 4669-4679
14. Karagiannis T.C., and El-Osta A. The paradox of histone deacetylase inhibitor-mediated modulation of cellular responses to radiation. Cell Cycle 5 (2006) 288-295
15. Kasim N.A., Whitehouse M., Ramachandran C., and Bermejo M. Molecular properties of WHO and provisional biopharmaceutical classification. Mol. Pharm. 1 (2004) 85-96
16. Kelly W.K., O'Connor O.A., Krug M.L., Chiao J.H., Heaney M., Curley T., MacGregore-Corteli B., Tong W., Secrist J.P., Schwartz L., Richardson S., Chu E., Olgac S., Marks P.A., Scher H., and Richon V.M. Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer. J. Clin. Oncol. 23 (2005) 3923-3931
17. Knipp G.T., Ho N.F., Barsuhn C.L., and Borchardt R.T. Paracellular diffusion in Caco-2 cell monolayers: effect of perturbation on the transport of hydrophilic compounds that vary in charge and size. J. Pharm. Sci. 86 (1997) 1105-1110
18. Konsoula R., and Barile F. Correlation of in vitro cytotoxicity with paracellular permeability in Caco-2 cells. Toxicol. In Vitro 19 (2005) 675-684
19. Kruger A., Soeltl R., Sopov I., Kopitz C., Arlt M., Magdolen V., Harbeck N., Gansbacher B., and Schmitt M. Hydroxamate-type matrix metalloproteinase inhibitor batimastat promotes liver metastasis. Cancer Res. 15 (2001) 1389-1392
20. Leo A., Hansch C., and Elkins D. Partition coefficients and their uses. Chem. Rev. 21 (1971) 525-616
21. Löbenberg R., and Amidon G.L. Solubility as a limited factor to drug absorption. In: Dressman J.B. (Ed). Oral Drug Absorption, Prediction and Assessment (2000), Marcel Dekker, New York
22. Marks P.A., Rifkind R.A., Richon V.M., Breslow R., Miller T., and Kelly W.K. Histone deacetylases and cancer: causes and therapy. Nat. Rev. Cancer 1 (2001) 194-202
23. McLaughlin F., and La Thangue N.B. Histone deacetylase inhibitors open new doors in cancer therapy. Biochem. Pharmacol. 68 (2004) 1139-1144
24. Meaney C., and O'Driscoll C. Mucus as a barrier to the permeability of hydrophilic and lipophilic compounds in the absence and presence of sodium taurocholate micellar systems using cell culture models. Eur. J. Pharm. Sci. 8 (1999) 167-175
25. Michaelides M.R., Dellaria J.F., Gong J., Holms J.H., Bouska J.J., Stacey J., Wada C.K., Heyman H.R., Curtin M.L., Guo Y., Goodfellow C.L., Elmore I.B., Albert D.H., Magoc T.J., Marcotte P.A., Morgan D.W., and Davidsen S.K. Biaryl ether retrohydroxamates as potent, long-lived, orally bioavailable MMP inhibitors. Bioorg. Med. Chem. Lett. 11 (2001) 1553-1556
26. Minucci S., and Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6 (2006) 38-51
27. Mulder G.J., and Meerman J.H. Sulfation and glucuronidation as competing pathways in the metabolism of hydroxamic acids: the role of N,O-sulfonation in chemical carcinogenesis of aromatic amines. Environ. Health Perspect. 49 (1983) 27-32
28. Pikul S., Ohler N.E., Ciszewski G., Laufersweiler M.C., Almstead N.G., De B., Natchus M.G., Hsieh L.C., Janusz M.J., Peng S.X., Branch T.M., King S.L., Taiwo Y.O., and Mieling G.E. Potent and selective carboxylic acid-based inhibitors of matrix metalloproteinases. J. Med. Chem. 44 (2001) 2499-2502
29. Remiszewski S.W., Sambucetti L.C., Atadja P., Bair K.W., Cornell W.D., Green M.A., Howell K.L., Jung M., Kwon P., Trogani N., and Walker H. Inhibitors of human histone deacetylase: synthesis and enzyme and cellular activity of straight chain hydroxamates. J. Med. Chem. 45 (2002) 753-757
30. Ryan Q.C., Headlee D., Acharya M., Sparreboom A., Trepel J.B., Ye J., Figg W.D., Hwang K., Chung E.J., Murgo A., Melillo G., Elsayed Y., Monga M., Kalnitskiy M., Zwiebel J., and Sausville E.A. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma. J. Clin. Oncol. 23 (2005) 3912-3922
31. Shukla M., Singh G., Sindhura B.G., Telang A.G., Rao G.S., and Malik J.K. Comp. Biochem. Physiol. C145 (2007) 528-532
32. Szotakova B., Baliharova V., Lamka J., Nozinova E., Wsol V., Velik J., Machala M., Neca J., Soucek P., Susova S., and Skalova L. Comparison of in vitro activities of biotransformation enzymes in pig, cattle, goat and sheep. Res. Vet. Sci. 76 (2004) 43-51
33. Suzuki T., Kouketsu A., Matsuura A., Kohara A., Ninomiya S., Kohda K., and Miyata N. Thiol-based SAHA analogues as potent histone deacetylase inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 3313-3317
34. Suzuki T., Matsura A., Kouketsu A., Nakagawa H., and Miyata N. Identification of a potent non-hydroxamate histone deacetylase inhibitor by mechanism-based drug design. Bioorg. Med. Chem. Lett. 15 (2005) 331-335
35. Vassiliou S., Mucha A., Cuniasse P., Georgiadis D., Lucet-Levannier K., Beau F., Kannan R., Murphy G., Knaeuper V., Rio M.C., Basset P., Yiotakis A., and Dive V.J. Phosphinic pseudo-tripeptides as potent inhibitors of matrix metalloproteinases: a structure-activity study. J. Med. Chem. 42 (1999) 2610-2620
36. Wakita K., Yoshimoto M., Miyamoto S., and Watanabe H. A method for calculation of the aqueous solubility of organic compounds by using new fragment solubility constants. Chem. Pharm. Bull. 34 (1986) 4663-4681
37. Yamashita S., Furubayashi T., Kataoka M., Sakane T., Sezaki H., and Tokuda H. Optimized conditions for prediction of intestinal drug permeability using Caco-2. Eur. J. Pharm. Sci. 10 (2000) 195-204
38. Zhao Y.H., Abraham M.H., Lee J., Hersey A., Luscombe C.N., Beck G., Sherborne B., and Cooper I. Rate-limited steps of human oral absorption and QSAR studies. Pharm. Res. 19 (2002) 1446-1457